Hepatitis C virus seroconversion among HIV-positive men who have sex with men with no history of injection drug use: Results from a clinical HIV cohort

• Published in: The Canadian journal of infectious diseases & medical microbiology Vol. 26; no. 1; pp. 17 - 22
• Main Authors: Burchell, Ann N, Gardner, Sandra L, Mazzulli, Tony, Manno, Michael, Raboud, Janet, Allen, Vanessa G, Bayoumi, Ahmed M, Kaul, Rupert, McGee, Frank, Millson, Peggy, Remis, Robert S, Wobeser, Wendy, Cooper, Curtis, Rourke, Sean B
• Format: Journal Article
• Language: English
• Published: Egypt Hindawi Limited 01.01.2015; Pulsus Group Inc
• Subjects: Drug abuse; Hepatitis; Hepatitis C; HIV; Human immunodeficiency virus; Infectious diseases; Men; Original; Seroconversion; Sexual behavior; Sexually transmitted diseases; STD; Studies; Viruses; Canada; HIV; Hepatitis C virus; Syphilis; Men who have sex with men; Incidence
• DOI: 10.1155/2015/689671
• ISSN: 1712-9532

Internationally, there is a growing recognition that hepatitis C virus (HCV) may be sexually transmitted among HIV-positive men who have sex with men (MSM). To report the first Canadian estimate of HCV seroincidence in 2000 to 2010 and its risk factors among HIV-positive MSM with no known history of injection drug use. Data from the Ontario HIV Treatment Network Cohort Study, an ongoing cohort of individuals in HIV care in Ontario, were analyzed. Data were obtained from medical charts, interviews and record linkage with the provincial public health laboratories. The analysis was restricted to 1534 MSM who did not report injection drug use and had undergone ≥2 HCV antibody tests, of which the first was negative (median 6.1 person-years [PY] of follow-up; sum 9987 PY). In 2000 to 2010, 51 HCV seroconversions were observed, an overall incidence of 5.1 per 1000 PY (95% CI 3.9 to 6.7). Annual incidence varied from 1.6 to 8.9 per 1000 PY, with no statistical evidence of a temporal trend. Risk for seroconversion was elevated among men who had ever had syphilis (adjusted HR 2.5 [95% CI 1.1 to 5.5) and men who had acute syphilis infection in the previous 18 months (adjusted HR 2.8 [95% CI 1.0 to 7.9]). Risk was lower for men who had initiated antiretroviral treatment (adjusted HR 0.49 [95% CI 0.25 to 0.95]). There were no statistically significant effects of age, ethnicity, region, CD4 cell count or HIV viral load. These findings suggest that periodic HCV rescreening may be appropriate in Ontario among HIV-positive MSM. Future research should seek evidence whether syphilis is simply a marker for high-risk sexual behaviour or networks, or whether it potentiates sexual HCV transmission among individuals with HIV.